Dual-mode microfluidic immunostaining device for diagnostic biomarkers detection and tumor microenvironment...

Area of Science:

• Oncology
• Biotechnology
• Pathology

Background:

• Rare tumors, such as primary central nervous system diffuse large B cell lymphoma (PCNS-DLBCL), present significant challenges in diagnosis and research due to limited tissue availability.
• Current methods for tissue analysis are often resource-intensive, consuming valuable tissue sections needed for comprehensive evaluation.

Purpose of the Study:

• To develop an innovative solution that overcomes the limitations of scarce tissue resources in rare tumor research.
• To create a streamlined, automated platform for both diagnostic and research applications in rare tumor pathology.

Main Methods:

• Development of a dual-mode microfluidic immunostaining (Dumi) device.
• Integration of diagnostic and research workflows onto a single automated platform.
• Utilizing Dumi to enable regional biomarker detection and multiplex tumor microenvironment (TME) mapping from minimal tissue samples (1-2 slides).

Main Results:

• Reduced tissue section consumption by over 90% compared to conventional methods.
• Enabled simultaneous diagnostic subtyping (≤16 biomarkers) and TME mapping.
• Demonstrated that tumor cell subpopulations actively shape their in situ microenvironment based on TME map analysis.

Conclusions:

• The Dumi device offers an efficient, cost-effective, and multifunctional approach to immunostaining.
• This technology overcomes critical limitations posed by scarce tissue resources in rare tumor diagnostics and research.
• Provides a clinically accessible solution for advancing the diagnosis and therapeutic strategies for rare tumors.